Antitumor Pharmacology - Quo Vadis ?

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)

Volume 16, 12 Issues, 2016

Download PDF Flyer

Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Michelle Prudhomme
Universite Blaise Pascal - C.N.R.S
Aubiere Cedex

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

Antitumor Pharmacology - Quo Vadis ?

Anti-Cancer Agents in Medicinal Chemistry, 4(5): 389-391.

Author(s): Christian Bailly, Jean-Marc Barret and Anna Kruczynski.

Affiliation: Institut de Recherches Pierre Fabre, Institut de Sciences et Technologies du Medicament de Toulouse, 3rue des Satellites, 31140 Toulouse, France.


In recent years, efforts have been made to improve the selectivity of anti-cancer agents via the targeting of cancer-specific proteins or signalisation pathways. Novel anticancer drugs inhibiting defined kinases, the proteasome, and selected growth factor receptors for examples have been developed with success for a few cancer types. But in parallel to these novel “soft” drugs, conventional “hard” cytotoxic molecules targeting DNA, topoisomerases or tubuline remain extensively used to treat solid tumors. This letter evokes the utility and limitations of the two drug categories and comments on new directions of the antitumor pharmacology taken to improve the efficacy of cancer chemotherapy and the development of new molecules.


antitumor pharmacology, anti-cancer agents, signalisation pathways, kinases, proteasome, soft drugs, cytotoxic molecules.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 4
Issue Number: 5
First Page: 389
Last Page: 391
Page Count: 3
DOI: 10.2174/1568011043352849
Price: $58

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science